Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Statement on NEJM Publication of Remdesivir Data From NIAID Study

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2020 | 08:08pm EDT

Foster City, Calif., May 22, 2020 - Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences, on data from the National Institute of Allergy and Infectious Diseases' (NIAID) study of our investigational antiviral drug remdesivir, published in The New England Journal of Medicine (NEJM):

'We are pleased that the findings from the NIAID trial of remdesivir in hospitalized patients with advanced COVID-19 have been published in a peer-reviewed medical journal. These findings support the use of remdesivir in this population, with the largest benefit observed among individuals who required oxygen supplementation but were not mechanically ventilated. We anticipate that results from our Phase 3 SIMPLE-Severe study, which is evaluating remdesivir in a similar population of COVID-19 patients requiring oxygen but not on mechanical ventilation, will be published in the near future. These data from the SIMPLE-Severe study support treatment of some patients for 5 days rather than 10 days, depending on clinical status.

Additionally, results from our Phase 3 SIMPLE-Moderate study, which is evaluating remdesivir in hospitalized patients with COVID-19 and lung involvement not requiring oxygen supplementation, are expected at the end of this month. This study should provide more information on the utility of 5 or 10 days of remdesivir versus standard of care in patients with earlier stages of disease.

Beyond the ongoing studies of remdesivir, we look forward to the initiation of combination studies of remdesivir to understand whether the addition of other drugs may enhance patient outcomes. Gilead is committed to continued studies of remdesivir to further advance our understanding of patient care for the treatment of COVID-19, and we remain engaged with governments and regulatory agencies around the world to help respond to this urgent public health emergency.'

About Remdesivir

Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials, and the safety and efficacy of remdesivir for the treatment of COVID-19 are not yet established. Remdesivir has not been approved by the U.S. FDA for any use. For information about the authorized use of remdesivir and mandatory requirements of the Emergency Use Authorization in the U.S., please review the Fact Sheet for Healthcare Providers and FDA Letter of Authorization available at www.gilead.com/remdesivir.

Forward Looking Statement

This statement includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. Remdesivir is an investigational drug that has not been approved by the FDA for any use, and it is not yet known if remdesivir is safe or effective for the treatment of COVID-19. There is the possibility of unfavorable results from ongoing and additional clinical trials involving remdesivir and the possibility that Gilead and other parties may be unable to complete one or more of such trials in the currently anticipated timelines or at all. Further, it is possible that Gilead may make a strategic decision to discontinue development of remdesivir or that FDA and other regulatory agencies may not approve remdesivir, and any marketing approvals, if granted, may have significant limitations on its use. As a result, remdesivir may never be successfully commercialized. In addition, Gilead may face challenges related to the allocation and geographical distribution of existing and future supply of remdesivir. If Gilead and its manufacturing partners are unable to sufficiently scale up the production of remdesivir in the currently anticipated timelines, Gilead may be unable to meet global supply needs. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Disclaimer

Gilead Sciences Inc. published this content on 22 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2020 00:07:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES
06/04Health Care Down As Analysts See Rally Overstretched -- Health Care Roundup
DJ
06/04ROCHE : test receives FDA emergency use approval for COVID-19 patients
RE
06/03GILEAD'S REMDESIVIR COULD SEE $7 BIL : analyst
RE
06/02GILEAD SCIENCES : Mark Genovese Joins Gilead to Lead Clinical Development of Com..
AQ
06/02GLOBAL MARKETS LIVE: Did insiders sell Gilead Sciences?
06/01Stocks rise on recovery hopes
RE
06/01Health Care Down After Pfizer, Gilead Setbacks In Drug Trials -- Health Care ..
DJ
06/01GILEAD SCIENCES : Names Executive to Lead Clinical Development of Co's Inflammat..
DJ
06/01WALL STREET STOCK EXCHANGE : Stocks Close Day With Modest Gains
DJ
06/01Coty, Beyond Meat rise; Pfizer, Gilead Sciences fall
AQ
More news
Financials (USD)
Sales 2020 22 415 M - -
Net income 2020 3 721 M - -
Net cash 2020 1 769 M - -
P/E ratio 2020 26,7x
Yield 2020 3,51%
Capitalization 96 273 M 96 273 M -
EV / Sales 2019
EV / Sales 2020 4,22x
Nbr of Employees 11 800
Free-Float 99,4%
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 80,44 $
Last Close Price 76,75 $
Spread / Highest target 26,4%
Spread / Average Target 4,81%
Spread / Lowest Target -24,4%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES18.11%96 273
VERTEX PHARMACEUTICALS21.35%68 887
REGENERON PHARMACEUTICALS59.00%60 628
WUXI APPTEC CO., LTD.24.27%26 697
GENMAB A/S29.16%18 949
BEIGENE, LTD.3.78%13 348